Comparative Pharmacology
Head-to-head clinical analysis: AMNESTROGEN versus ETHINYL ESTRADIOL LEVONORGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTROGEN versus ETHINYL ESTRADIOL LEVONORGESTREL.
AMNESTROGEN vs ETHINYL ESTRADIOL; LEVONORGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropins (FSH and LH) from the anterior pituitary, inhibiting ovulation. Also increases cervical mucus viscosity and induces endometrial changes that reduce implantation likelihood.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
1 tablet (0.03 mg ethinyl estradiol / 0.15 mg levonorgestrel) orally once daily for 21 consecutive days, followed by 7 days of placebo
None Documented
None Documented
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Ethinyl estradiol: ~13-27 hours (terminal); Levonorgestrel: ~16-33 hours (terminal). Clinically, steady-state is reached within 5-7 days; elimination half-life supports once-daily dosing with potential accumulation.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Renal: Ethinyl estradiol ~40% as glucuronide and sulfate conjugates; levonorgestrel ~20% as metabolites. Fecal: Ethinyl estradiol ~60%; levonorgestrel ~80% via biliary excretion.
Category C
Category D/X
Estrogen
Estrogen